IL6 and metabolic dysfunction-associated steatohepatitis: The results showed that rosavin treatment significantly improved the liver function tests and lipid panel, decreased the hepatic expression of IL-6 and TNF-α proteins, and diminished the percentage and stage of steatosis, inflammation, and fibrosis as compared with the untreated NASH group.